{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:04:12Z","timestamp":1791227052338,"version":"4.1.0"},"reference-count":95,"publisher":"American Association for the Advancement of Science (AAAS)","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":323,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["EXC 2180 - 390900677"],"award-info":[{"award-number":["EXC 2180 - 390900677"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001646","name":"Robert Bosch Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020655","name":"European Health and Digital Executive Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["csbj.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Comput Struct Biotechnol J"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.csbj.2025.11.047","type":"journal-article","created":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T15:23:20Z","timestamp":1763911400000},"page":"592-608","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Advancing rare disease therapeutics through digital twins: Opportunities in drug development and precision dosing"],"prefix":"10.34133","volume":"28","author":[{"given":"Charlotte Maria Ursula","family":"Dette","sequence":"first","affiliation":[{"name":"Clinical Pharmacy, Saarland University, Saarbr\u00fccken 66123, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Alberg","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy, Saarland University, Saarbr\u00fccken 66123, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeon","family":"R\u00fcdesheim","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy, Saarland University, Saarbr\u00fccken 66123, Germany"},{"name":"Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart 70376, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Selzer","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy, Saarland University, Saarbr\u00fccken 66123, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima Zahra","family":"Marok","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy, Saarland University, Saarbr\u00fccken 66123, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola Luigi","family":"Bragazzi","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy, Saarland University, Saarbr\u00fccken 66123, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Maria","family":"Fuhr","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy, Saarland University, Saarbr\u00fccken 66123, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Brunak","sequence":"additional","affiliation":[{"name":"Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewan R.","family":"Pearson","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Endocrinology and Reproductive Biology, Ninewells Hospital and School of Medicine, University of Dundee, Dundee, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Zahn","sequence":"additional","affiliation":[{"name":"Crowd Pharma GmbH, Pforzheim 75179, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Kiritsi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical Center \u2013 University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany"},{"name":"First Department of Dermatology, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schwab","sequence":"additional","affiliation":[{"name":"Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart 70376, Germany"},{"name":"Departments of Clinical Pharmacology, Pharmacy and Biochemistry, University of T\u00fcbingen, T\u00fcbingen 72076, Germany"},{"name":"Cluster of Excellence iFIT (EXC2180) \u201cImage-Guided and Functionally Instructed Tumor Therapies\u201d, University of T\u00fcbingen, T\u00fcbingen 72076, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Lehr","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy, Saarland University, Saarbr\u00fccken 66123, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"e_1_3_4_2_2","unstructured":"National Aeronautics and Space Administration. Digital Twins and Living Models at NASA (2021). Available: \u3008https:\/\/ntrs.nasa.gov\/citations\/20210023699\u3009. Accessed 2024 Nov 10."},{"key":"e_1_3_4_3_2","first-page":"526","volume-title":"Digital Twins for Industry 4.0 and Beyond2019 IEEE International Conference on Industrial Engineering and Engineering Management (IEEM)","author":"Hsu Y.","year":"2019","unstructured":"Hsu Y., Chiu J.-M. and Liu J.S.: Digital Twins for Industry 4.0 and Beyond. 2019 IEEE International Conference on Industrial Engineering and Engineering Management (IEEM). : IEEE 2019: 526."},{"key":"e_1_3_4_4_2","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2018.00031","article-title":"Digital twins in health care: ethical implications of an emerging engineering paradigm","volume":"9","author":"Bruynseels K.","year":"2018","unstructured":"Bruynseels K., Santoni de Sio F. and van den Hoven J.: Digital twins in health care: ethical implications of an emerging engineering paradigm. Front Genet 2018; 9.","journal-title":"Front Genet"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.patter.2024.101028"},{"key":"e_1_3_4_6_2","doi-asserted-by":"crossref","DOI":"10.3389\/fdgth.2022.1007784","article-title":"al. Exploring approaches for predictive cancer patient digital twins: opportunities for collaboration and innovation","volume":"4","author":"Stahlberg E.A.","year":"2022","unstructured":"Stahlberg E.A., Abdel-Rahman M., Aguilar B., Asadpoure A. and Beckman R.A.: al. Exploring approaches for predictive cancer patient digital twins: opportunities for collaboration and innovation. Front Digit Health 2022; 4.","journal-title":"Front Digit Health"},{"key":"e_1_3_4_7_2","article-title":"The potential of the medical digital twin in diabetes management: a review","volume":"10","author":"Chu Y.","year":"2023","unstructured":"Chu Y., Li S., Tang J. and Wu H.: The potential of the medical digital twin in diabetes management: a review. Front Med 2023; 10.","journal-title":"Front Med"},{"key":"e_1_3_4_8_2","unstructured":"Gartner Hype Cycle. Available: \u3008https:\/\/www.gartner.com\/en\/articles\/hype-cycle-for-emerging-technologies\u3009. Accessed 2024 Nov 18."},{"key":"e_1_3_4_9_2","unstructured":"Gen Li. A New Regulatory Road in Clinical Trials: Digital Twins. Appl Clin Trials 2024;33. Available: \u3008https:\/\/www.appliedclinicaltrialsonline.com\/view\/new-regulatory-road-clinical-trials-digital-twins\u3009. Accessed 2025 July 31."},{"key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1001\/journalofethics.2015.17.8.pfor2-1508","article-title":"Policymaking for orphan drugs and its challenges","volume":"17","author":"Taeho Greg Rhee","year":"2015","unstructured":"Taeho Greg Rhee : Policymaking for orphan drugs and its challenges. AMA J Ethics 2015; 17: 776.","journal-title":"AMA J Ethics"},{"key":"e_1_3_4_11_2","unstructured":"EU Definition Rare Diseases Available: \u3008https:\/\/health.ec.europa.eu\/rare-diseases-and-european-reference-networks\/rare-diseases_en\u3009. Accessed 2024 Nov 19."},{"key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","article-title":"Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database","volume":"28","author":"Nguengang Wakap S.","year":"2020","unstructured":"Nguengang Wakap S., Lambert D.M., Olry A., Rodwell C., Gueydan C. et al: Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet 2020; 28: 165.","journal-title":"Eur J Hum Genet"},{"key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1177\/0883073813495959","article-title":"Clinical trials in rare disease","volume":"28","author":"Augustine E.F.","year":"2013","unstructured":"Augustine E.F., Adams H.R. and Mink J.W.: Clinical trials in rare disease. J Child Neurol 2013; 28: 1142.","journal-title":"J Child Neurol"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.168"},{"key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13023-022-02299-5","article-title":"The national economic burden of rare disease in the United States in 2019","volume":"17","author":"Yang G.","year":"2022","unstructured":"Yang G., Cintina I., Pariser A., Oehrlein E., Sullivan J. et al: The national economic burden of rare disease in the United States in 2019. Orphanet J Rare Dis 2022; 17: 163.","journal-title":"Orphanet J Rare Dis"},{"key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s13023-024-03319-2","article-title":"Time to diagnosis for a rare disease: managing medical uncertainty. A qualitative study","volume":"19","author":"Phillips C.","year":"2024","unstructured":"Phillips C., Parkinson A., Namsrai T., Chalmers A., Dews C. et al: Time to diagnosis for a rare disease: managing medical uncertainty. A qualitative study. Orphanet J Rare Dis 2024; 19: 297.","journal-title":"Orphanet J Rare Dis"},{"key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-024-00505-1","article-title":"Rare diseases: challenges and opportunities for research and public health","volume":"10","author":"Taruscio D.","year":"2024","unstructured":"Taruscio D. and Gahl W.A.: Rare diseases: challenges and opportunities for research and public health. Nat Rev Dis Prim 2024; 10: 13.","journal-title":"Nat Rev Dis Prim"},{"key":"e_1_3_4_18_2","unstructured":"U.S. Food and Drug Administration. Critical Path Initiative (2004). Available: \u3008https:\/\/www.fda.gov\/science-research\/science-and-research-special-topics\/critical-path-initiative\u3009. Accessed 2025 Aug 14."},{"key":"e_1_3_4_19_2","unstructured":"U.S. Food and Drug Administration. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products - Executive Summary (2004). Available: \u3008https:\/\/wayback.archive-it.org\/7993\/20180125032208\/https:\/\/www.fda.gov\/ScienceResearch\/SpecialTopics\/CriticalPathInitiative\/CriticalPathOpportunitiesReports\/ucm077262.htm#execsummary\u3009. Accessed 2025 Aug 14."},{"key":"e_1_3_4_20_2","unstructured":"U.S. Food and Drug Administration: FDA-2016-D-3969 - Physiologically Based Pharmacokinetic Analyses - Format and Content Guidance for Industry (2018). Available: \u3008https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/physiologically-based-pharmacokinetic-analyses-format-and-content-guidance-industry\u3009. Accessed 2025 Aug 1."},{"key":"e_1_3_4_21_2","unstructured":"U.S. Food and Drug Administration: FDA-2019-D-2398 - Population Pharmacokinetics Guidance for Industry (2022). Available: \u3008https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/population-pharmacokinetics\u3009. Accessed 2025 Aug 1."},{"key":"e_1_3_4_22_2","unstructured":"U.S. Food and Drug Administration: Artificial Intelligence in Drug Manufacturing (2023). Available: \u3008https:\/\/www.fda.gov\/news-events\/fda-voices\/fda-releases-two-discussion-papers-spur-conversation-about-artificial-intelligence-and-machine\u3009. Accessed 2025 Aug 1."},{"key":"e_1_3_4_23_2","unstructured":"U.S. Food and Drug Administration: FDA-2024-D-4689 - Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products (2025). Available: \u3008https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological\u3009. Accessed 2025 Aug 1."},{"key":"e_1_3_4_24_2","unstructured":"European Medicines Agency: Multi-annual artificial intelligence workplan 2023-2028: HMA-EMA joint Big Data Steering Group (2024). \u3008https:\/\/www.ema.europa.eu\/en\/news\/artificial-intelligence-workplan-guide-use-ai-medicines-regulation\u3009. Accessed 2025 Aug 1."},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12049"},{"key":"e_1_3_4_26_2","unstructured":"European Medicines Agency: EMA\/CHMP\/458101\/2016 - Reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation (2019). Available: \u3008https:\/\/www.ema.europa.eu\/en\/reporting-physiologically-based-pharmacokinetic-pbpk-modelling-simulation-scientific-guideline\u3009. Accessed 2025 Aug 1."},{"key":"e_1_3_4_27_2","unstructured":"European Medicines Agency: CHMP\/EWP\/185990\/06 - Reporting the results of population pharmacokinetic analyses (2008). Available: \u3008https:\/\/www.ema.europa.eu\/en\/reporting-results-population-pharmacokinetic-analyses-scientific-guideline\u3009. Accessed 2025 Aug 1."},{"key":"e_1_3_4_28_2","unstructured":"European Medicines Agency: EMA\/CHMP\/ICH\/496426\/2024 - ICH M15 guideline on general principles for model-informed drug development (2025). Available: \u3008https:\/\/www.ema.europa.eu\/en\/ich-m15-guideline-general-principles-model-informed-drug-development-step-2b-scientific-guideline\u3009. Accessed 2025 Aug 1."},{"key":"e_1_3_4_29_2","unstructured":"U.S. Food and Drug Administration: Digital Health Technologies (DHTs) for Drug Development (2025). \u3008https:\/\/www.fda.gov\/science-research\/science-and-research-special-topics\/digital-health-technologies-dhts-drug-development#framework\u3009 Accessed 2025 Oct 21."},{"key":"e_1_3_4_30_2","unstructured":"U.S. Food and Drug Administration. U.S. Food and Drug Administration: FDA-2017-D-6569 - Clinical Decision Support Software (2022). \u3008https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-decision-support-software\u3009 Accessed 2025 Nov 11."},{"key":"e_1_3_4_31_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/psp.2013.41","article-title":"Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development","volume":"2","author":"Jones H.","year":"2013","unstructured":"Jones H. and Rowland-Yeo K.: Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacomet Syst Pharm 2013; 2: 1.","journal-title":"CPT Pharmacomet Syst Pharm"},{"key":"e_1_3_4_32_2","first-page":"401","article-title":"Basic concepts of pharmacokinetic\/pharmacodynamic (PK\/PD) modelling","volume":"35","author":"Meibohm B.","year":"1997","unstructured":"Meibohm B. and Derendorf H.: Basic concepts of pharmacokinetic\/pharmacodynamic (PK\/PD) modelling. Int J Clin Pharm Ther 1997; 35: 401. PMID: 9352388.","journal-title":"Int J Clin Pharm Ther"},{"key":"e_1_3_4_33_2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ddtec.2004.09.006","article-title":"Physiology-based pharmacokinetic modeling: ready to be used","volume":"1","author":"Schmitt W.","year":"2004","unstructured":"Schmitt W. and Willmann S.: Physiology-based pharmacokinetic modeling: ready to be used. Drug Discov Today Technol 2004; 1: 449.","journal-title":"Drug Discov Today Technol"},{"key":"e_1_3_4_34_2","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s11095-020-02964-z","article-title":"Physiologically based pharmacokinetic models of probenecid and furosemide to predict transporter mediated drug-drug interactions","volume":"37","author":"Britz H.","year":"2020","unstructured":"Britz H., Hanke N., Taub M.E., Wang T., Prasad B. et al: Physiologically based pharmacokinetic models of probenecid and furosemide to predict transporter mediated drug-drug interactions. Pharm Res 2020; 37: 250.","journal-title":"Pharm Res"},{"key":"e_1_3_4_35_2","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.3390\/ijerph20043473","article-title":"The role of \u201cphysiologically based pharmacokinetic model (PBPK)\u201d new approach methodology (NAM) in pharmaceuticals and environmental chemical risk assessment","volume":"20","author":"Deepika D.","year":"2023","unstructured":"Deepika D. and Kumar V.: The role of \u201cphysiologically based pharmacokinetic model (PBPK)\u201d new approach methodology (NAM) in pharmaceuticals and environmental chemical risk assessment. Int J Environ Res Public Health 2023; 20: 3473.","journal-title":"Int J Environ Res Public Health"},{"key":"e_1_3_4_36_2","unstructured":"Servier Medical Art by Servier is licensed under a Creative Commons Attribution 4.0 Unported License. Available: \u3008https:\/\/creativecommons.org\/licenses\/by\/4.0\/\u3009. Accessed: 2024-2025 Oct 2024 \u2013 Aug 2025."},{"key":"e_1_3_4_37_2","unstructured":"Virtual Physiological Human Initiative \u2013 VPHI available: \u3008https:\/\/www.vph-institute.org\/mission-and-vision.html\u3009 Accessed 2025 Oct. 28."},{"key":"e_1_3_4_38_2","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1109\/JBHI.2021.3090469","article-title":"Possible contexts of use for in silico trials methodologies: a consensus-based review","volume":"25","author":"Viceconti M.","year":"2021","unstructured":"Viceconti M., Emili L., Afshari P., Courcelles E., Curreli C. et al: Possible contexts of use for in silico trials methodologies: a consensus-based review. IEEE J Biomed Health Inf 2021; 25: 3977.","journal-title":"IEEE J Biomed Health Inf"},{"key":"e_1_3_4_39_2","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2165\/11593210-000000000-00000","article-title":"Impact of pharmacometric analyses on new drug approval and labelling decisions","volume":"50","author":"Lee J.Y.","year":"2011","unstructured":"Lee J.Y., Garnett C.E., Gobburu J.V.S., Bhattaram V.A., Brar S. et al: Impact of pharmacometric analyses on new drug approval and labelling decisions. Clin Pharm 2011; 50: 627.","journal-title":"Clin Pharm"},{"key":"e_1_3_4_40_2","doi-asserted-by":"crossref","unstructured":"Zaph S. Leiser R.J. Tao M. Kaddi C. Xu C. Application of Quantitative Systems Pharmacology Approaches to Support Pediatric Labeling in Rare Diseases 2024. https:\/\/doi.org\/10.1007\/164_2024_734.","DOI":"10.1007\/164_2024_734"},{"key":"e_1_3_4_41_2","article-title":"Quantitative systems pharmacology-based digital twins approach supplements clinical trial data for enzyme replacement therapies in pompe disease","author":"Kaddi C.","year":"2024","unstructured":"Kaddi C., Tao M., Bergeler S., George K., Geerts H. et al: Quantitative systems pharmacology-based digital twins approach supplements clinical trial data for enzyme replacement therapies in pompe disease. Clin Pharm Ther 2024; .","journal-title":"Clin Pharm Ther"},{"key":"e_1_3_4_42_2","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.3451","article-title":"Quantitative systems pharmacology models: potential tools for advancing drug development for rare diseases","author":"Neves-Zaph S.","year":"2024","unstructured":"Neves-Zaph S. and Kaddi C.: Quantitative systems pharmacology models: potential tools for advancing drug development for rare diseases. Clin Pharm Ther 2024; .","journal-title":"Clin Pharm Ther"},{"key":"e_1_3_4_43_2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221336","article-title":"The use of a predictive statistical model to make a virtual control arm for a clinical trial","volume":"14","author":"Switchenko J.M.","year":"2019","unstructured":"Switchenko J.M., Heeke A.L., Pan T.C. and Read W.L.: The use of a predictive statistical model to make a virtual control arm for a clinical trial. PLoS One 2019; 14: e0221336.","journal-title":"PLoS One"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-021-01626-4"},{"key":"e_1_3_4_45_2","doi-asserted-by":"crossref","first-page":"815","DOI":"10.3233\/ADR-210039","article-title":"Computational approaches for supporting combination therapy in the post-aducanumab era in Alzheimer\u2019s disease","volume":"5","author":"Geerts H.","year":"2021","unstructured":"Geerts H. and van der Graaf P.: Computational approaches for supporting combination therapy in the post-aducanumab era in Alzheimer\u2019s disease. J Alzheimers Dis Rep 2021; 5: 815.","journal-title":"J Alzheimers Dis Rep"},{"key":"e_1_3_4_46_2","doi-asserted-by":"crossref","DOI":"10.1088\/2516-1091\/acdc71","article-title":"A systematic review of cardiac in-silico clinical trials","volume":"5","author":"Rodero C.","year":"2023","unstructured":"Rodero C., Baptiste T.M.G., Barrows R.K., Keramati H., Sillett C.P. et al: A systematic review of cardiac in-silico clinical trials. Prog Biomed Eng 2023; 5: 032004.","journal-title":"Prog Biomed Eng"},{"key":"e_1_3_4_47_2","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/j.xphs.2023.06.019","article-title":"Quantitative systems pharmacology for rare disease drug development","volume":"112","author":"Bai J.P.","year":"2023","unstructured":"Bai J.P., Wang J., Zhang Y., Wang L. and Jiang X.: Quantitative systems pharmacology for rare disease drug development. J Pharm Sci 2023; 112: 2313.","journal-title":"J Pharm Sci"},{"key":"e_1_3_4_48_2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s13239-024-00769-4","article-title":"Computer-generated clinical decision-making in the treatment of pulmonary atresia with intact ventricular septum","volume":"16","author":"Y\u0131ld\u0131r\u0131m C.","year":"2025","unstructured":"Y\u0131ld\u0131r\u0131m C., Ural B., Odemis E., Donmazov S. and Pekkan K.: Computer-generated clinical decision-making in the treatment of pulmonary atresia with intact ventricular septum. Cardiovasc Eng Technol 2025; 16: 222.","journal-title":"Cardiovasc Eng Technol"},{"key":"e_1_3_4_49_2","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1454785","article-title":"A quantitative systems pharmacology (QSP) platform for preclinical to clinical translation of in-vivo CRISPR-Cas therapy","volume":"15","author":"Desai D.A.","year":"2024","unstructured":"Desai D.A., Schmidt S. and Cristofoletti R.: A quantitative systems pharmacology (QSP) platform for preclinical to clinical translation of in-vivo CRISPR-Cas therapy. Front Pharm 2024; 15.","journal-title":"Front Pharm"},{"key":"e_1_3_4_50_2","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/psp4.12518","article-title":"Leveraging quantitative systems pharmacology approach into development of human recombinant follistatin fusion protein for duchenne muscular dystrophy","volume":"9","author":"Nguyen H.Q.","year":"2020","unstructured":"Nguyen H.Q., Iskenderian A., Ehmann D., Jasper P., Zhang Z. et al: Leveraging quantitative systems pharmacology approach into development of human recombinant follistatin fusion protein for duchenne muscular dystrophy. CPT Pharmacomet Syst Pharm 2020; 9: 342.","journal-title":"CPT Pharmacomet Syst Pharm"},{"key":"e_1_3_4_51_2","doi-asserted-by":"crossref","DOI":"10.1002\/psp4.70063","article-title":"Quantitative systems pharmacology modeling of platelet responses to recombinant ADAMTS13 in patients with congenital thrombotic thrombocytopenic purpura","author":"McBride C.","year":"2025","unstructured":"McBride C., Jiang J., Zhang Z., Tolsma J., Patwari P. et al: Quantitative systems pharmacology modeling of platelet responses to recombinant ADAMTS13 in patients with congenital thrombotic thrombocytopenic purpura. CPT Pharmacomet Syst Pharm 2025; .","journal-title":"CPT Pharmacomet Syst Pharm"},{"key":"e_1_3_4_52_2","unstructured":"Orphanet - Knowledge on rare diseases and orphan drugs available: \u3008https:\/\/www.orpha.net\/en\/disease\/detail\/547?name=non%20hodgkin%20lymphoma&mode=name\u3009 Accessed 2025 Oct. 27."},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13501"},{"key":"e_1_3_4_54_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1208\/s12248-023-00784-8","article-title":"Model-informed approach supporting approval of nexviazyme (avalglucosidase alfa-ngpt) in pediatric patients with late-onset pompe disease","volume":"25","author":"Li R.-J.","year":"2023","unstructured":"Li R.-J., Ma L., Drozda K., Wang J., Punnoose A.R. et al: Model-informed approach supporting approval of nexviazyme (avalglucosidase alfa-ngpt) in pediatric patients with late-onset pompe disease. AAPS J 2023; 25: 16.","journal-title":"AAPS J"},{"key":"e_1_3_4_55_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105913","article-title":"Development and verification of an endogenous PBPK model to inform hydrocortisone replacement dosing in children and adults with cortisol deficiency","volume":"165","author":"Bonner J.J.","year":"2021","unstructured":"Bonner J.J., Burt H., Johnson T.N., Whitaker M.J., Porter J. et al: Development and verification of an endogenous PBPK model to inform hydrocortisone replacement dosing in children and adults with cortisol deficiency. Eur J Pharm Sci 2021; 165: 105913.","journal-title":"Eur J Pharm Sci"},{"key":"e_1_3_4_56_2","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/cpt.3203","article-title":"A Generative and causal pharmacokinetic model for factor <scp>VIII<\/scp> in Hemophilia a: a machine learning framework for continuous model refinement","volume":"115","author":"Janssen A.","year":"2024","unstructured":"Janssen A., Smalbil L., Bennis F.C., Cnossen M.H. and Math\u00f4t R.A.A.: A Generative and causal pharmacokinetic model for factor <scp>VIII<\/scp> in Hemophilia a: a machine learning framework for continuous model refinement. Clin Pharm Ther 2024; 115: 881.","journal-title":"Clin Pharm Ther"},{"key":"e_1_3_4_57_2","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1038\/s41598-018-20737-y","article-title":"In silico clinical trials for pediatric orphan diseases","volume":"8","author":"Carlier A.","year":"2018","unstructured":"Carlier A., Vasilevich A., Marechal M., de Boer J. and Geris L.: In silico clinical trials for pediatric orphan diseases. Sci Rep 2018; 8: 2465.","journal-title":"Sci Rep"},{"key":"e_1_3_4_58_2","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","article-title":"What is polypharmacy? A systematic review of definitions","volume":"17","author":"Masnoon N.","year":"2017","unstructured":"Masnoon N., Shakib S., Kalisch-Ellett L. and Caughey G.E.: What is polypharmacy? A systematic review of definitions. BMC Geriatr 2017; 17: 230.","journal-title":"BMC Geriatr"},{"key":"e_1_3_4_59_2","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","article-title":"Incidence of adverse drug reactions in hospitalized patients","volume":"279","author":"Lazarou J.","year":"1998","unstructured":"Lazarou J., Pomeranz B.H. and Corey P.N.: Incidence of adverse drug reactions in hospitalized patients. JAMA 1998; 279: 1200.","journal-title":"JAMA"},{"key":"e_1_3_4_60_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","article-title":"Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients","volume":"329","author":"Pirmohamed M.","year":"2004","unstructured":"Pirmohamed M., James S., Meakin S., Green C., Scott A.K. et al: Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15.","journal-title":"BMJ"},{"key":"e_1_3_4_61_2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/jcph.6133","article-title":"Determination of vatiquinone drug-drug interactions, as CYP450 perpetrator and victim, using physiologically based pharmacokinetic (pbpk) modeling and simulation","volume":"65","author":"Lee L.","year":"2025","unstructured":"Lee L., Okudaira N., Murase K., Kong R. and Jones H.M.: Determination of vatiquinone drug-drug interactions, as CYP450 perpetrator and victim, using physiologically based pharmacokinetic (pbpk) modeling and simulation. J Clin Pharmacol 2025; 65: 160.","journal-title":"J Clin Pharmacol"},{"key":"e_1_3_4_62_2","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/cpt.2738","article-title":"Physiologically-based pharmacokinetic model development, validation, and application for prediction of eliglustat drug\u2013drug interactions","volume":"112","author":"Sahasrabudhe S.A.","year":"2022","unstructured":"Sahasrabudhe S.A., Cheng S., Al-Kofahi M., Jarnes J.R., Weinreb N.J. et al: Physiologically-based pharmacokinetic model development, validation, and application for prediction of eliglustat drug\u2013drug interactions. Clin Pharm Ther 2022; 112: 1254.","journal-title":"Clin Pharm Ther"},{"key":"e_1_3_4_63_2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1208\/s12248-019-0309-y","article-title":"Simulating the IMpact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 substrates in patients with neuromyelitis optica or neuromyelitis optica spectrum disorders in different ethnic populations","volume":"21","author":"Machavaram K.K.","year":"2019","unstructured":"Machavaram K.K., Endo-Tsukude C., Terao K., Gill K.L., Hatley O.J. et al: Simulating the IMpact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 substrates in patients with neuromyelitis optica or neuromyelitis optica spectrum disorders in different ethnic populations. AAPS J 2019; 21: 42.","journal-title":"AAPS J"},{"key":"e_1_3_4_64_2","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/hae.15027","article-title":"Development of a plasminogen population PK model supporting prophylactic replacement therapy for Plasminogen deficient patients within the WAPPS-Hemo platform","volume":"30","author":"Chelle P.","year":"2024","unstructured":"Chelle P., Hajducek D., Thibaudeau K., Hobson N., Iorio A. et al: Development of a plasminogen population PK model supporting prophylactic replacement therapy for Plasminogen deficient patients within the WAPPS-Hemo platform. Haemophilia 2024; 30: 988.","journal-title":"Haemophilia"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18921"},{"key":"e_1_3_4_66_2","unstructured":"EB Research Network Available: \u3008https:\/\/www.eb-researchnetwork.org\/research\/what-is-eb\/#:\u223c:text=With%20a%20prevalence%20of%20only some%20subtypes%20are%20very%20rare\u3009. Accessed 2024 Oct 28."},{"key":"e_1_3_4_67_2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13023-021-01811-7","article-title":"A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa","volume":"16","author":"Tang J.Y.","year":"2021","unstructured":"Tang J.Y., Marinkovich M.P., Lucas E., Gorell E., Chiou A. et al: A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa. Orphanet J Rare Dis 2021; 16: 175.","journal-title":"Orphanet J Rare Dis"},{"key":"e_1_3_4_68_2","unstructured":"Vyjuvek - Topical Gene Therapy in EB. Available: \u3008https:\/\/www.vyjuvekhcp.com\/about-vyjuvek\/\u3009. Accessed 2024 Oct 29."},{"key":"e_1_3_4_69_2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0140-6736(25)00778-0","article-title":"Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial","volume":"406","author":"Tang J.Y.","year":"2025","unstructured":"Tang J.Y., Marinkovich M.P., Wiss K., McCarthy D., Truesdale A. et al: Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial. Lancet 2025; 406: 163.","journal-title":"Lancet"},{"key":"e_1_3_4_70_2","unstructured":"Filsuvez Birch Triterpenes Topical Gel. Available: \u3008www.filsuvez.com\u3009. Accessed 2025 Aug 24."},{"key":"e_1_3_4_71_2","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s13023-020-01467-9","article-title":"Small molecule drug development for rare genodermatoses \u2013 evaluation of the current status in epidermolysis bullosa","volume":"15","author":"Wally V.","year":"2020","unstructured":"Wally V., Reisenberger M., Kitzm\u00fcller S. and Laimer M.: Small molecule drug development for rare genodermatoses \u2013 evaluation of the current status in epidermolysis bullosa. Orphanet J Rare Dis 2020; 15: 292.","journal-title":"Orphanet J Rare Dis"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042243"},{"key":"e_1_3_4_73_2","unstructured":"DEBRA International EB Information. Available: \u3008https:\/\/www.debra-international.org\/what-is-eb\u3009. Accessed 2024 Nov 19."},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddmod.2020.10.001"},{"key":"e_1_3_4_75_2","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/pde.13722","article-title":"Epidermolysis bullosa simplex\u2013generalized severe type due to keratin 5 p.Glu477Lys mutation: genotype-phenotype correlation and in silico modeling analysis","volume":"36","author":"Lalor L.","year":"2019","unstructured":"Lalor L., Titeux M., Palisson F., Fuentes I., Yubero M.J. et al: Epidermolysis bullosa simplex\u2013generalized severe type due to keratin 5 p.Glu477Lys mutation: genotype-phenotype correlation and in silico modeling analysis. Pedia Dermatol 2019; 36: 132.","journal-title":"Pedia Dermatol"},{"key":"e_1_3_4_76_2","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.3390\/jcm13133742","article-title":"Epidemiological characteristics of inherited epidermolysis bullosa in an eastern european population","volume":"13","author":"Suru A.","year":"2024","unstructured":"Suru A., D\u0103nescu S., C\u0103linescu-St\u00eencanu A., Iorga D., Dasc\u0103lu M. et al: Epidemiological characteristics of inherited epidermolysis bullosa in an eastern european population. J Clin Med 2024; 13: 3742.","journal-title":"J Clin Med"},{"key":"e_1_3_4_77_2","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1093\/ced\/llaf009","article-title":"Milestone events in recessive dystrophic epidermolysis bullosa: findings of the PEBLES study","volume":"50","author":"Mellerio J.E.","year":"2025","unstructured":"Mellerio J.E., Pillay E.I., Sollesta K., Thiel K.E., Zimmerman G. et al: Milestone events in recessive dystrophic epidermolysis bullosa: findings of the PEBLES study. Clin Exp Dermatol 2025; 50: 1125.","journal-title":"Clin Exp Dermatol"},{"key":"e_1_3_4_78_2","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/bjd.18475","article-title":"Natural history of growth and anaemia in children with epidermolysis bullosa: a retrospective cohort study*","volume":"182","author":"Reimer A.","year":"2020","unstructured":"Reimer A., Hess M., Schwieger-Briel A., Kiritsi D., Schauer F. et al: Natural history of growth and anaemia in children with epidermolysis bullosa: a retrospective cohort study*. Br J Dermatol 2020; 182: 1437.","journal-title":"Br J Dermatol"},{"key":"e_1_3_4_79_2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jdin.2020.12.007","article-title":"A comparison study of outcome measures for epidermolysis bullosa: epidermolysis bullosa disease activity and scarring index (ebdasi) and the instrument for scoring clinical outcomes of research for epidermolysis bullosa (iscorEB)","volume":"2","author":"Rogers C.L.","year":"2021","unstructured":"Rogers C.L., Gibson M., Kern J.S., Martin L.K., Robertson S.J. et al: A comparison study of outcome measures for epidermolysis bullosa: epidermolysis bullosa disease activity and scarring index (ebdasi) and the instrument for scoring clinical outcomes of research for epidermolysis bullosa (iscorEB). JAAD Int 2021; 2: 134.","journal-title":"JAAD Int"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(22)00234-5"},{"key":"e_1_3_4_81_2","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2014.71"},{"key":"e_1_3_4_82_2","unstructured":"European Health Data & Evidence Network (EHDEN) available: \u3008https:\/\/www.ehden.eu\/vision-and-mission\/\u3009 Accessed 2025 Otc. 21."},{"key":"e_1_3_4_83_2","unstructured":"MIDATA Switzerland available: \u3008https:\/\/www.midata.coop\/en\/home\/\u3009 Accessed 2025 Oct. 21."},{"key":"e_1_3_4_84_2","unstructured":"DEBRA UK - EB support and resources available: \u3008https:\/\/www.debra.org.uk\/get-support\/eb-support-and-resources\/\u3009 Accessed 2025 Oct. 21."},{"key":"e_1_3_4_85_2","unstructured":"RareConnect by EURORDIS available: \u3008https:\/\/www.rareconnect.org\/de\u3009 Accessed 2025 Oct. 21."},{"key":"e_1_3_4_86_2","unstructured":"EURORDIS - Rare Diseases Europe available: \u3008https:\/\/www.eurordis.org\/who-we-are\/our-vision-mission\/\u3009 Accessed 2025 Oct. 21."},{"key":"e_1_3_4_87_2","unstructured":"Orphanet available: \u3008https:\/\/www.orpha.net\/\u3009 Accessed 2025 Oct. 21."},{"key":"e_1_3_4_88_2","unstructured":"European Reference Networks SKIN available: \u3008https:\/\/ern-skin.eu\/what-is-the-ernskin\/\u3009 Accessed 2025 Oct. 21."},{"key":"e_1_3_4_89_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41746-024-01073-0","article-title":"Digital twins for health: a scoping review","volume":"7","author":"Katsoulakis E.","year":"2024","unstructured":"Katsoulakis E., Wang Q., Wu H., Shahriyari L., Fletcher R. et al: Digital twins for health: a scoping review. NPJ Digit Med 2024; 7: 77.","journal-title":"NPJ Digit Med"},{"key":"e_1_3_4_90_2","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/cpt.659","article-title":"Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future","volume":"101","author":"Darwich A.S.","year":"2017","unstructured":"Darwich A.S., Ogungbenro K., Vinks A.A., Powell J.R., Reny J. et al: Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future. Clin Pharm Ther 2017; 101: 646.","journal-title":"Clin Pharm Ther"},{"key":"e_1_3_4_91_2","unstructured":"Critical Path Institute. Available: \u3008https:\/\/c-path.org\/what-we-do\/\u3009 Accessed 2025 July 31."},{"key":"e_1_3_4_92_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41746-024-01421-0","article-title":"Generating unseen diseases patient data using ontology enhanced generative adversarial networks","volume":"8","author":"Sun C.","year":"2025","unstructured":"Sun C. and Dumontier M.: Generating unseen diseases patient data using ontology enhanced generative adversarial networks. NPJ Digit Med 2025; 8: 4.","journal-title":"NPJ Digit Med"},{"key":"e_1_3_4_93_2","first-page":"4607","volume-title":"Synthesizing Multimodal Electronic Health Records via Predictive Diffusion ModelsProceedings of the 30th ACM SIGKDD Conference on Knowledge Discovery and Data Mining","author":"Zhong Y.","year":"2024","unstructured":"Zhong Y., Wang X., Wang J., Zhang X., Wang Y. et al: Synthesizing Multimodal Electronic Health Records via Predictive Diffusion Models. Proceedings of the 30th ACM SIGKDD Conference on Knowledge Discovery and Data Mining. New York, NY, USA: ACM 2024: 4607."},{"key":"e_1_3_4_94_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41746-023-00822-x","article-title":"Synthetic electronic health records generated with variational graph autoencoders","volume":"6","author":"Nikolentzos G.","year":"2023","unstructured":"Nikolentzos G., Vazirgiannis M., Xypolopoulos C., Lingman M. and Brandt E.G.: Synthetic electronic health records generated with variational graph autoencoders. NPJ Digit Med 2023; 6: 83.","journal-title":"NPJ Digit Med"},{"key":"e_1_3_4_95_2","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.3390\/electronics13193909","article-title":"Bias mitigation via synthetic data generation: a review","volume":"13","author":"Shahul Hameed M.A.","year":"2024","unstructured":"Shahul Hameed M.A., Qureshi A.M. and Kaushik A.: Bias mitigation via synthetic data generation: a review. Electron 2024; 13: 3909.","journal-title":"Electron"},{"key":"e_1_3_4_96_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2024.09.030"}],"container-title":["Computational and Structural Biotechnology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2001037025005148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2001037025005148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.1016\/j.csbj.2025.11.047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T20:19:05Z","timestamp":1778012345000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.1016\/j.csbj.2025.11.047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":95,"alternative-id":["10.1016\/j.csbj.2025.11.047"],"URL":"https:\/\/doi.org\/10.1016\/j.csbj.2025.11.047","relation":{},"ISSN":["2001-0370"],"issn-type":[{"value":"2001-0370","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing rare disease therapeutics through digital twins: Opportunities in drug development and precision dosing","name":"articletitle","label":"Article Title"},{"value":"Computational and Structural Biotechnology Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.csbj.2025.11.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Research Network of Computational and Structural Biotechnology. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}